The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes

被引:23
|
作者
He, Xingxing
Su, Jiaorong
Ma, Xiaojing [1 ]
Lu, Wei
Zhu, Wei
Wang, Yufei
Bao, Yuqian
Zhou, Jian [1 ]
机构
[1] Shanghai Jiao Tong Univ, Affiliated Sixth Peoples Hosp 6, Dept Endocrinol & Metab, Shanghai 200233, Peoples R China
关键词
Type 2 diabetes mellitus; Growth differentiation factor 15; Lower extremity atherosclerotic disease; Femoral intima-media thickness; Body mass index; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; MEMBER; MORTALITY; BIOMARKER; CYTOKINE; OBESITY; GDF-15;
D O I
10.1186/s12933-020-01020-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Clinical and basic investigations have indicated a significant association between circulating growth differentiation factor 15 (GDF15) and cardiovascular disease; however, the relationship between GDF15 and lower extremity atherosclerotic disease (LEAD) has been less studied. The present study aimed to explore the association between GDF15 and LEAD in Chinese patients with type 2 diabetes mellitus (T2DM). Considering that obesity is an important factor associated with circulating GDF15 levels, whether the relationship between serum GDF15 levels and LEAD is affected by body mass index (BMI) was also analysed. Methods A total of 376 hospitalized T2DM patients were enrolled (161 with LEAD and 215 without LEAD). A sandwich enzyme-linked immunosorbent assay was used to detect the serum GDF15 levels. The femoral intima-media thickness (F-IMT) and LEAD were assessed by ultrasonography. Results Patients with LEAD had significantly higher serum GDF15 levels than those without LEAD, regardless of whether their BMI was < 25 kg/m(2) or >= 25 kg/m(2) (both P < 0.05). Serum GDF15 levels were independently positively related to the F-IMT (standardized beta = 0.162, P = 0.002). After adjusting for confounding factors, per 1-standard deviation (SD) increase in the serum GDF15 levels was significantly related to an approximately 1.4-fold increased risk of LEAD in the total population (P < 0.05). Regardless of whether the BMI was < 25 kg/m(2) or >= 25 kg/m(2), this association remained significant, with approximately 1.6- and 1.4-fold increased risks of LEAD, respectively (both P < 0.05). Conclusions High serum GDF15 levels were significantly correlated with an increased risk of LEAD in T2DM patients, and this relationship was independent of BMI.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Association between variability in body mass index and development of type 2 diabetes: Panasonic cohort study
    Okada, Hiroshi
    Hamaguchi, Masahide
    Habu, Momoko
    Kurogi, Kazushiro
    Murata, Hiroaki
    Ito, Masato
    Fukui, Michiaki
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [42] Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels
    Cuevas-Ramos, Daniel
    Almeda-Valdes, Paloma
    Gomez-Perez, Francisco J.
    Elena Meza-Arana, Clara
    Cruz-Bautista, Ivette
    Arellano-Campos, Olimpia
    Navarrete-Lopez, Mariana
    Aguilar-Salinas, Carlos A.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2010, 163 (03) : 469 - 477
  • [43] Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure
    Al-kuraishy, Hayder M. M.
    Al-Gareeb, Ali I. I.
    Alexiou, Athanasios
    Papadakis, Marios
    Nadwa, Eman Hassan
    Albogami, Sarah M. M.
    Alorabi, Mohammed
    Saad, Hebatallah M. M.
    Batiha, Gaber El-Saber
    JOURNAL OF DIABETES, 2022, 14 (12) : 806 - 814
  • [44] Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesity
    Asrih, Mohamed
    Sinturel, Flore
    Dubos, Richard
    Guessous, Idris
    Pataky, Zoltan
    Dibner, Charna
    Jornayvaz, Francois R.
    Gariani, Karim
    ENDOCRINE CONNECTIONS, 2022, 11 (07)
  • [45] Growth hormone treatment downregulates serum leptin levels in children independent of changes in body mass index
    Elimam, A
    Lindgren, AC
    Norgren, S
    Kamel, A
    Skwirut, C
    Bang, P
    Marcus, C
    HORMONE RESEARCH, 1999, 52 (02) : 66 - 72
  • [46] Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case-control study
    Natali, Andrea
    Nesti, Lorenzo
    Venturi, Elena
    Shore, Angela C.
    Khan, Faisel
    Gooding, Kim
    Gates, Phillip E.
    Looker, Helen C.
    Dove, Fiona
    Goncalves, Isabel
    Persson, Margaretha
    Nilsson, Jan
    DIABETES OBESITY & METABOLISM, 2019, 21 (02) : 412 - 416
  • [47] Association of serum growth differentiation factor-15 levels with the risks of death and vascular events in patients with ischemic stroke: The role of diabetes
    Yang, Pinni
    Zhu, Zhengbao
    Shi, Mengyao
    Yin, Jieyun
    Zang, Yuhan
    Zhong, Chongke
    Wang, Aili
    Peng, Hao
    Xu, Tian
    Guo, Daoxia
    Xu, Tan
    Chen, Jing
    Zhang, Yonghong
    He, Jiang
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2022, 32 (03) : 616 - 623
  • [48] Association of Lower Plasma Fetuin-A Levels With Peripheral Arterial Disease in Type 2 Diabetes
    Epaso, Luis H.
    Ginwala, Naeema
    Qasim, Atif N.
    Mehta, Nehal N.
    Dlugash, Rachel
    Kapoor, Shiv
    Schwartz, Stanley
    Schutta, Mark
    Iqbal, Nayyar
    Mohler, Emile R., III
    Reilly, Muredach P.
    DIABETES CARE, 2010, 33 (02) : 408 - 410
  • [49] Independent association between the visceral adiposity index and microalbuminuria in patients with newly diagnosed type 2 diabetes
    Wen, Jia
    Yuan, Hong
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2020, 36 (01)
  • [50] Body Mass Index and Risk of All-Cause and Cardiovascular Disease Mortality in Patients With Type 2 Diabetes Mellitus
    Wu, Cui
    Li, Yuandong
    Li, Na
    Chan, Ka Kei
    Piao, Chunli
    ENDOCRINOLOGY, 2025, 166 (04)